Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 146

1.

Prospects for treatment of pediatric vitreoretinal diseases with vascular endothelial growth factor inhibition.

Lin KL, Hirose T, Kroll AJ, Lou PL, Ryan EA.

Semin Ophthalmol. 2009 Mar-Apr;24(2):70-6. doi: 10.1080/08820530902800108. Review.

PMID:
19373689
2.

Intravitreal and intracameral bevacizumab to treat neovascular complications of retinopathy of prematurity.

dell'Omo R, Kulkarni A, Franks WA.

Acta Ophthalmol. 2008 Sep;86(6):698-700. No abstract available.

3.

Elevated vascular endothelial growth factor level in Coats' disease and possible therapeutic role of bevacizumab.

He YG, Wang H, Zhao B, Lee J, Bahl D, McCluskey J.

Graefes Arch Clin Exp Ophthalmol. 2010 Oct;248(10):1519-21. doi: 10.1007/s00417-010-1366-1. Epub 2010 Apr 9.

PMID:
20379736
4.

Anti-vascular endothelial growth factor therapy for ocular neovascular disease.

Andreoli CM, Miller JW.

Curr Opin Ophthalmol. 2007 Nov;18(6):502-8. Review.

PMID:
18163003
5.

Vitrectomy after intravitreal bevacizumab (Avastin) for retinal detachment in retinopathy of prematurity.

Kychenthal A, Dorta P.

Retina. 2010 Apr;30(4 Suppl):S32-6. doi: 10.1097/IAE.0b013e3181ca146b.

PMID:
20224474
6.

Rapid regression of retinal hemorrhage and neovascularization in a case of familial exudative vitreoretinopathy treated with intravitreal bevacizumab.

Tagami M, Kusuhara S, Honda S, Tsukahara Y, Negi A.

Graefes Arch Clin Exp Ophthalmol. 2008 Dec;246(12):1787-9. doi: 10.1007/s00417-008-0949-6. Epub 2008 Sep 16.

PMID:
18795314
7.

Bevacizumab for Coats' disease with exudative retinal detachment and risk of vitreoretinal traction.

Ramasubramanian A, Shields CL.

Br J Ophthalmol. 2012 Mar;96(3):356-9. doi: 10.1136/bjophthalmol-2011-300141. Epub 2011 Jun 7.

PMID:
21653215
8.

Anti-angiogenic therapy in the management of retinopathy of prematurity.

Drenser KA.

Dev Ophthalmol. 2009;44:89-97. doi: 10.1159/000223949. Epub 2009 Jun 3. Review.

PMID:
19494656
9.

[Molecular pathogenesis of ocular vascular disease--anti-angiogenesis as a therapeutic concept].

Joussen AM.

Dtsch Med Wochenschr. 2007 Jun 8;132(23):1268-72. Review. German.

PMID:
17541869
10.

Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.

Honda S, Hirabayashi H, Tsukahara Y, Negi A.

Graefes Arch Clin Exp Ophthalmol. 2008 Jul;246(7):1061-3. doi: 10.1007/s00417-008-0786-7. Epub 2008 Mar 5.

PMID:
18320201
11.

Antivascular endothelial growth factor for retinopathy of prematurity.

Mintz-Hittner HA, Best LM.

Curr Opin Pediatr. 2009 Apr;21(2):182-7. doi: 10.1097/MOP.0b013e32832925f9. Review.

PMID:
19300261
12.

Paradoxical vascular-fibrotic reaction after intravitreal bevacizumab for retinopathy of prematurity.

Zepeda-Romero LC, Liera-Garcia JA, Gutiérrez-Padilla JA, Valtierra-Santiago CI, Avila-Gómez CD.

Eye (Lond). 2010 May;24(5):931-3. doi: 10.1038/eye.2009.156. Epub 2009 Jun 26. No abstract available. Erratum in: Eye (Lond). 2010 Jan;24(1):202. Cardenas-Lamas, L J [corrected to Avila-Gómez, C D].

PMID:
19557020
13.

The expanding role of vascular endothelial growth factor inhibitors in ophthalmology.

Stewart MW.

Mayo Clin Proc. 2012 Jan;87(1):77-88. doi: 10.1016/j.mayocp.2011.10.001. Review.

14.

Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity.

Travassos A, Teixeira S, Ferreira P, Regadas I, Travassos AS, Esperancinha FE, Prieto I, Pires G, van Velze R, Valido A, Machado Mdo C.

Ophthalmic Surg Lasers Imaging. 2007 May-Jun;38(3):233-7.

PMID:
17552391
16.

[Pharmacological treatment for retinopathy of prematurity].

Stahl A, Agostini H, Jandeck C, Lagrèze W.

Ophthalmologe. 2011 Aug;108(8):777-85; quiz 786-7. doi: 10.1007/s00347-011-2371-4. German.

PMID:
21853221
17.
18.

Intravitreous bevacizumab as anti-vascular endothelial growth factor therapy for retinopathy of prematurity: a morphologic study.

Kong L, Mintz-Hittner HA, Penland RL, Kretzer FL, Chévez-Barrios P.

Arch Ophthalmol. 2008 Aug;126(8):1161-3. doi: 10.1001/archophthalmol.2008.1. No abstract available.

PMID:
18695118
19.

Effects of intravitreal bevacizumab and laser in retinopathy of prematurity therapy on the development of peripheral retinal vessels.

Lee JY, Chae JB, Yang SJ, Yoon YH, Kim JG.

Graefes Arch Clin Exp Ophthalmol. 2010 Sep;248(9):1257-62. doi: 10.1007/s00417-010-1375-0.

PMID:
20393741
20.

Emerging evidence concerning systemic safety of anti-VEGF agents--should ophthalmologists be concerned?

Lim LS, Cheung CM, Mitchell P, Wong TY.

Am J Ophthalmol. 2011 Sep;152(3):329-31. doi: 10.1016/j.ajo.2011.05.040. No abstract available.

PMID:
21855670
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk